ATE229945T1 - Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole - Google Patents

Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole

Info

Publication number
ATE229945T1
ATE229945T1 AT99912221T AT99912221T ATE229945T1 AT E229945 T1 ATE229945 T1 AT E229945T1 AT 99912221 T AT99912221 T AT 99912221T AT 99912221 T AT99912221 T AT 99912221T AT E229945 T1 ATE229945 T1 AT E229945T1
Authority
AT
Austria
Prior art keywords
treatment
cmv infections
thiadiazoles
cmv
thiadiazoles suitable
Prior art date
Application number
AT99912221T
Other languages
English (en)
Inventor
Steven R Turner
Suvit Thaisrivongs
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE229945T1 publication Critical patent/ATE229945T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT99912221T 1998-03-19 1999-03-16 Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole ATE229945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7852898P 1998-03-19 1998-03-19
PCT/US1999/003744 WO1999047507A2 (en) 1998-03-19 1999-03-16 1,3,4-thiadiazoles useful for the treatment of cmv infections

Publications (1)

Publication Number Publication Date
ATE229945T1 true ATE229945T1 (de) 2003-01-15

Family

ID=22144610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912221T ATE229945T1 (de) 1998-03-19 1999-03-16 Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole

Country Status (11)

Country Link
US (1) US6150385A (de)
EP (1) EP1064273B1 (de)
JP (1) JP2002506858A (de)
AT (1) ATE229945T1 (de)
AU (1) AU743489B2 (de)
CA (1) CA2320167A1 (de)
DE (1) DE69904576T2 (de)
DK (1) DK1064273T3 (de)
ES (1) ES2189404T3 (de)
NZ (1) NZ507032A (de)
WO (1) WO1999047507A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2914200A (en) 1999-03-08 2000-09-28 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
PL373484A1 (en) * 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
ES2375134T3 (es) 2003-07-30 2012-02-27 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos.
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003318A (es) * 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP5094398B2 (ja) 2004-09-20 2012-12-12 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環式誘導体およびステアロイル−CoAデサチュラーゼのメディエータとしてのそれらの使用
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
WO2006109817A1 (ja) * 2005-04-06 2006-10-19 Banyu Pharmaceutical Co., Ltd. 1,4-置換ピペラジン誘導体
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
MX2009002019A (es) 2006-08-24 2009-03-09 Novartis Ag Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros.
EP2240171B1 (de) * 2008-01-09 2014-08-13 Molecular Insight Pharmaceuticals, Inc. Carboanhydrase-IX-Hemmer
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
FR2945289A1 (fr) 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
RU2012154447A (ru) 2010-05-12 2014-06-20 Вандербилт Юниверсити Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
RU2448961C1 (ru) * 2011-02-03 2012-04-27 Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") Фармацевтическая композиция, обладающая противовоспалительной, бронхолитической, противотуберкулезной активностями
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
WO2014070976A1 (en) * 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
EP3545978B1 (de) 2013-01-14 2021-09-08 Molecular Insight Pharmaceuticals, Inc. Radiopharmazeutika auf triazinbasis und strahlungsbildgebungsmittel
MY198018A (en) 2016-04-06 2023-07-26 Lnnovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
SI3692039T1 (sl) 2017-10-05 2023-04-28 Innovative Molecules Gmbh Enantomeri substituiranih tiazolov kot protivirusne spojine
KR20230170813A (ko) 2018-09-12 2023-12-19 노파르티스 아게 항바이러스 피리도피라진디온 화합물
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8148047A0 (it) * 1981-03-18 1981-03-18 Manetti & Roberts Italo Brit Composti organici derivati da 2-ami no-5-(o-solfamidofenil)-1,3,4-tiadiazolo loro applicazione terapeutica e procedimento per la loro preparazione
CA1307222C (en) * 1985-12-16 1992-09-08 Eli Lilly And Company Thiadiazole antiviral agents
EP0591486A1 (de) * 1992-04-22 1994-04-13 PEUSCHEL, Karin, Elisabeth Immunaktivierende und damit antivirale wirking von 4- 3-(subst.-amino)-2-hydroxypropoxy]-1,2,5-thiadiazolverbindungen
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
JPH07149748A (ja) * 1993-09-30 1995-06-13 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体及びその製造法
CA2199822A1 (en) * 1994-09-22 1996-03-28 Katsushi Ijichi Arylthiadiazole derivative and antiviral agent containing the same

Also Published As

Publication number Publication date
DE69904576T2 (de) 2003-07-10
AU3063999A (en) 1999-10-11
JP2002506858A (ja) 2002-03-05
ES2189404T3 (es) 2003-07-01
WO1999047507A3 (en) 1999-12-09
EP1064273B1 (de) 2002-12-18
DE69904576D1 (de) 2003-01-30
CA2320167A1 (en) 1999-09-23
EP1064273A2 (de) 2001-01-03
NZ507032A (en) 2003-06-30
DK1064273T3 (da) 2003-03-31
US6150385A (en) 2000-11-21
AU743489B2 (en) 2002-01-24
WO1999047507A2 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
ATE229945T1 (de) Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
HK1033463A1 (en) 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
ES2139195T3 (es) Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
EA200000840A1 (ru) Антивирусные производные пиримидина
ATE295355T1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
ATE264846T1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
BR9908332A (pt) Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
DE69830751D1 (de) Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen
ES2160046A1 (es) Derivados pentapeptidicos.
ES2080297T3 (es) Derivados 17-g(b)-sustituido-4-aza-5g(a)-androstan-3-ona y procedimiento de preparacion de estos.
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
IL108091A0 (en) Inhibitors of hiv protease useful for the treatment of aids
TR200402534T4 (tr) Viral enfeksiyonların tedavisinde yararlı oksazinokuinolonlar.
DE69617005D1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
EA200100711A1 (ru) Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
CY1112574T1 (el) Οκταπεπτιδιο το οποιο εχει αντιαγγειογενετικη δραστικοτητα
ECSP972314A (es) Derivados de aminoacidos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1064273

Country of ref document: EP

REN Ceased due to non-payment of the annual fee